Keyphrases
Post-transplantation Cyclophosphamide (PTCy)
66%
Graft-versus-host Disease (GvHD)
60%
Haploidentical Transplantation
38%
Pediatric
33%
HLA-haploidentical
28%
Bone Marrow Transplantation
24%
Hematological Malignancies
23%
HLA Matching
20%
Nonmyeloablative
19%
Severe Aplastic Anemia
18%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
17%
Alternative Donor
16%
Myeloablative
16%
Overall Survival
15%
Myeloablative Conditioning
15%
Young Adult Patients
14%
Cumulative Incidence
14%
Non-relapse Mortality
12%
Allogeneic Bone Marrow Transplantation
12%
Pretransplant
12%
High Dose
11%
Haploidentical
11%
Haploidentical Donor
10%
Confidence Interval
10%
Human Leukocyte Antigen
10%
Minimal Residual Disease
10%
Matched Related
10%
Acute Leukemia
10%
Cyclophosphamide
9%
High Risk
9%
Pediatric Patients
9%
Reduced-intensity Conditioning
8%
Event-free Survival
8%
HLA-matched Donor
8%
Tacrolimus
8%
Myelodysplastic Syndrome
8%
Graft Failure
8%
Hematopoietic Cell Transplantation
8%
COVID-19
8%
Graft-versus-host Disease Prophylaxis
7%
Engraftment
7%
Alternative Donor Transplantation
7%
Haploidentical BMT
7%
Total Body Irradiation
7%
Transplant-related Mortality
7%
T-cell Replete
7%
Blood or Marrow Transplantation
7%
Pediatric Oncology
7%
Relapsed Lymphoma
6%
Relapsed or Refractory
6%
Medicine and Dentistry
Cyclophosphamide
53%
Pediatrics
49%
Bone Marrow Transplantation
45%
Graft Versus Host Reaction
35%
Hematologic Malignancy
30%
Hematopoietic Stem Cell Transplantation
24%
Transplantation
23%
Disease
20%
Drug Megadose
19%
Cumulative Incidence
19%
Overall Survival
16%
Whole Body Radiation
15%
Graft Failure
15%
Alternative Donor
14%
Cell Transplantation
13%
Hematopoietic Stem Cell
13%
Acute Leukemia
13%
Engraftment
13%
Acute Graft Versus Host Disease
12%
Minimal Residual Disease
11%
T Cell
11%
Event Free Survival
9%
Malignant Neoplasm
9%
Computer Assisted Tomography
9%
Aplastic Anemia
9%
Haploidentical Transplantation
9%
Enteric Feeding
9%
COVID-19
9%
Pediatrics Patient
8%
Clinical Trial
8%
Nonmyeloablative Conditioning
8%
Myeloablative Conditioning
8%
Childhood Cancer
8%
Sinusitis
7%
Conditioning
7%
Symptom
7%
Hemoglobinopathy
7%
Infection
7%
Oncology
6%
Chronic Graft Versus Host Disease
6%
Neoplasm
6%
Matched Donor
6%
Prophylaxis
6%
Myelodysplastic Syndrome
5%
Predictive Factor
5%
Nutritional Support
5%
Human Leukocyte Antigen
5%
Donor Lymphocyte Infusion
5%
Adolescent Medicine
5%
Platelet
5%
Immunology and Microbiology
Cyclophosphamide
100%
Bone Marrow Transplantation
82%
Graft-Versus-Host Disease
58%
Conditioning
44%
Transplant Procedure
32%
Drug Megadose
27%
Overall Survival
23%
Hematopoietic Stem Cell Transplantation
21%
T Cell
21%
Acute Graft Versus Host Disease
21%
Chronic Graft Versus Host Disease
18%
Aplastic Anemia
18%
Hematopoietic Cell
16%
Cell Transplantation
16%
Engraftment
16%
Tacrolimus
11%
Allogeneic Bone Marrow Transplantation
11%
Myeloid
10%
Event Free Survival
10%
Human Leukocyte Antigen
10%
Lymphocyte
10%
Recurrence Free Survival
9%
Mycophenolic Acid
9%
Progression Free Survival
7%
Allogeneic Hematopoietic Stem Cell Transplantation
6%
Chimera
6%
Host
5%
Natural Killer Cell
5%
Immune Reconstitution
5%
Platelet
5%